ENVALITH
株式会社総医研ホールディングス logo

Soiken Holdings Inc.

2385・Growth Market・Services

Official website
株式会社総医研ホールディングス logo
Soiken Holdings Inc.2385

Business

So-Iken Holdings, Inc. is a holding company established in 1994 as a bio-venture spun out of Osaka University. Centered on biomarker technology, the company operates five businesses: (1) contract clinical evaluation testing for foods and other products (Biological Evaluation System), (2) contracted specific health guidance for health insurance associations (Healthcare Support), (3) placenta-based cosmetics (Cosmetics), (4) mail-order health supplements centered on Imida Peptide (Health Supplements), and (5) development of functional materials such as lactoferrin (Functional Materials Development). Its main customers span a wide range, including food and pharmaceutical companies, health insurance associations, and general consumers. The company is listed on the Tokyo Stock Exchange Growth Market.

Business Model

The company builds evidence using biomarker technology derived from university research outcomes, and maintains multiple revenue streams: (1) contracted testing fees, (2) contracted health guidance fees (a service business model with high operating leverage), (3) mail-order and wholesale sales of cosmetics and health supplements, and (4) OEM supply and technology licensing of functional ingredients. All business operations are self-funded, maintaining a zero-interest-bearing-debt financial structure. As of the end of FY2025 (ending June 2025), the company held cash and cash equivalents of ¥4,958 million.

Company Strengths

As of the end of FY2025 (ended June 2025), interest-bearing debt stood at zero, and cash and cash equivalents totaled ¥4,958 million (approximately 73% of total assets of ¥6,812 million). All funding needs are met through internal resources, preserving capacity for upfront investment in M&A and R&D. Net assets stood at ¥6,037 million, with an equity ratio of approximately 89%.

"Imida Peptide," born out of the fatigue research project, was accepted for notification as Japan's first product able to display the functional claim "reduces feelings of physical fatigue arising in daily life" under the Foods with Function Claims system that took effect in April 2015. This pioneering track record underpins the company's competitive advantage in evidence-building know-how.

All health insurance associations and similar entities are obligated to implement specific health guidance and data health plans, providing a stable institutional demand base. In FY2025 (ended June 2025), the Healthcare Support business achieved sales of ¥688 million (up 15.7% year on year) and operating profit of ¥106 million (up 15.3% year on year). As a service business without merchandise procurement, it enjoys high operating leverage.

ENVALITH's Perspective

For the cumulative nine months of the third quarter of FY2026 (ending March 2026), the company recorded consolidated operating profit of ¥325 million and quarterly net profit attributable to owners of the parent of ¥244 million, marking a clear turnaround from the operating loss of ¥123 million and net loss of ¥150 million in the same period of the previous year. The full-year earnings forecast has also been revised upward (net sales of ¥3,860 million, operating profit of ¥200 million, net profit of ¥120 million), with the results of structural reforms clearly reflected in the figures. However, the fact that the full-year operating profit forecast of ¥200 million falls short of the cumulative nine-month operating profit of ¥325 million is due to anticipated recording of strategic upfront investments and costs related to the termination of the BB Laboratories business in the fourth quarter, and investors should pay close attention to the scale of expenses in the fourth quarter.

In the cumulative nine months of the current third quarter, the company recorded ¥96 million in extraordinary income from gain on transfer of trademark rights, and extraordinary losses of ¥127 million from business restructuring losses and ¥8 million from losses on office consolidation. Quarterly net profit before income taxes and other adjustments was ¥298 million, and the difference from ordinary profit of ¥338 million is due to the net amount of extraordinary income/losses (-¥39 million). The recording of temporary costs associated with structural reforms may continue going forward, making it important to distinguish between the underlying performance level based on ordinary profit and net profit including extraordinary income/losses. The full-year net profit forecast of ¥120 million is significantly below the cumulative nine-month figure of ¥244 million, and the scale of extraordinary losses to be recorded in the fourth quarter will be a focal point.

Multiple strategic initiatives are proceeding simultaneously, including system development investment toward building a "comprehensive healthcare platform" utilizing medical DX, the absorption-type merger of NRL Pharma into Nihon Yobo Iyaku (effective April 2026), and the launch of a new cosmetics brand. Whether these upfront investments will translate into profits from the next fiscal year onward will be a key point for medium- to long-term evaluation. Meanwhile, net sales remain on a declining trend, down 12.1% year-on-year, and the challenge remains to achieve both profitability improvement through structural reforms and recovery in sales scale. M&A-related activities are also underway, and the materialization of external growth is another point of attention.

Growth Strategy

Building a comprehensive healthcare platform centered on medical DX and creating synergies through subsidiary reorganization

Building a medical DX platform integrating online health consultations/medical care, second opinions, mail-in testing, PHR utilization, and self-medication support e-commerce. System development investment is being implemented in Q4. The company aims to build a platform that comprehensively supports everything from prevention to treatment and improved health literacy, leveraging its physician network and evidence-acquisition know-how.

Nihon Yobo Iyaku (Japan Preventive Medicine), which sells health supplements (Imida Peptide), absorbed NRL Pharma, which develops functional materials (lactoferrin, etc.), through a merger effective April 1, 2026. The aim is to integrate business processes from material development to product sales, reduce indirect costs, and expand into the femcare market by inheriting NRL Pharma's numerous lactoferrin-related patents.

Following the cessation of business activities by BB Laboratories (end of March 2026), the placenta product cosmetics business was transferred to Nihon Yobo Iyaku. A new cosmetics brand under the concept of "scientifically addressing skin fatigue" is being launched, aiming to sustain and expand the business through cross-selling that leverages Nihon Yobo Iyaku's e-commerce sales know-how and customer base. Product development investment is being implemented in Q4.

In FY2026 (ending June 2026), profit margins improved significantly through targeted focus on repeat-purchase customers and cost efficiency measures (cumulative operating profit of ¥329 million through Q3). With an eye toward growth in the next fiscal year, the company is resuming expansion of advertising investment from Q4, pursuing a strategy that balances the recovery of sales scale with maintaining profit levels.

M&A-related activities aimed at accelerating growth are being advanced in Q4, exploring external growth opportunities to enhance the functionality and content of the comprehensive healthcare platform. Specific targets and scale have not been disclosed.

Last updated: July 17, 2026